Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study

Joint Bone Spine

Volumn 77, Issue 4, 2010, Pages 325-329

  Saougou, Ioanna ^a   Markatseli, Theodora E ^a   Voulgari, Paraskevi V ^a   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Ankylosing spondylitis; Anti TNF agents; ASAS; BASDAI; Infliximab

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ANTINUCLEAR FACTOR TEST; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HERPES LABIALIS; HUMAN; PSORIASIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; ANTAGONISTS AND INHIBITORS; BLOOD; DOSE RESPONSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954623685     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.014     Document Type: Article

References (33)

1. Braun J., van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 2003, 12:1097-1109.
2. Alamanos Y., Papadopoulos N.G., Voulgari P.V., et al. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. Rheumatology (Oxford) 2004, 43:615-618.
3. Gran J.T., Husby G. The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 1993, 22:319-334.
4. McGonagle D., Marzo-Ortega H., Benjamin M., Emery P. Report on the Second International Enthesitis Workshop. Arthritis Rheum 2003, 48:896-905.
5. Zhang X., Aubin J.E., Inman R.D. Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol 2003, 15:387-393.
6. Khan M.A. Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases. Clin Exp Rheumatol 2002, 20(6 Suppl. 28):S6-10.
7. Creemers M.C., Franssen M.J., van de Putte L.B., et al. Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995, 22:1104-1107.
8. Roychowdhury B., Bintley-Bagot S., Bulgen D.Y., et al. Is methotrexate effective in ankylosing spondylitis?. Rheumatology (Oxford) 2002, 41:1330-1332.
9. Dougados M., vam der Linden S., Leirisalo-Repo M., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
10. McGonagle D., Gibbon W., O'Connor P., et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998, 41:694-700.
11. Braun J., Bollow M., Eggens U., et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroilitis in spondylarthropathy patients. Arthritis Rheum 1994, 37:1039-1045.
12. Muche B., Bollow M., François R.J., et al. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 2003, 48:1374-1384.
13. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
14. Laloux L., Voisin M.C., Allain J., et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001, 60:316-321.
15. Bollow M., Fischer T., Reisshauer H., et al. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000, 59:135-140.
16. Braun J., Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies. Ann Rheum Dis 2000, 59:404-407.
17. Brandt J., Haibel H., Reddig J., et al. Treatment of patients with severe ankylosing spondylitis with infliximab-a one-year follow-up. Arthritis Rheum 2001, 44:2936-2937.
18. Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab-a double-blind placebo controlled multicenter trial. Lancet 2002, 359:1187-1193.
19. Temekonidis T.I., Alamanos Y., Nikas S.N., et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12-month study. Ann Rheum Dis 2003, 62:1218-1220.
20. Nikas S.N., Alamanos Y., Voulgari P.V., et al. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005, 64:940-942.
21. Griffoul I., Giraudeau B., Mulleman D., et al. Infliximab for treating axial spondyloarthropathy in everyday practice. Joint Bone Spine 2009, 76:39-43.
22. Venetsanopoulou A.I., Voulgari P.V., Alamanos Y., et al. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int 2007, 27:935-939.
23. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
24. Garrett S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
25. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
26. van der Linden S.M., Rentsch H.U., et al. The association between ankylosing spondylitis, acute anterior uveitis and HLA-B27: the results of a Swiss family study. Br J Rheumatol 1988, 27(Suppl. 2):39-41.
27. Exarchou S., Voulgari P., Markatseli T., et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009, 4:1-4.
28. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:2368-2376.
29. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
30. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
31. Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
32. Braun J., Baraliakos X., Brandt J., et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3years. Rheumatology (Oxford) 2005, 44:670-676.
33. Braun J., Baraliakos X., Listing J., et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.